Literature DB >> 20981006

Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles.

M Pirmohamed1.   

Abstract

The journey from the discovery of a biomarker to its implementation in clinical practice is long and complex. There are many obstacles along the way, including lack of consistent evidence, inadequate validation of the biomarker, inadequate evidence of clinical utility, operational barriers to clinical implementation, and inadequate evidence of operational effectiveness or impact in clinical care. Multipronged approaches, incorporating input from many disciplines working together, will be required to overcome the obstacles to the clinical implementation and to allow the progression of clinical practice from the current paradigm of a one-size-fits-all strategy to more personalized treatment pathways that are more predictable in terms of health gains.

Mesh:

Substances:

Year:  2010        PMID: 20981006     DOI: 10.1038/clpt.2010.245

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Pharmacogenomics in clinical practice: reality and expectations.

Authors:  C Lee Ventola
Journal:  P T       Date:  2011-07

2.  Visual automated fluorescence electrophoresis provides simultaneous quality, quantity, and molecular weight spectra for genomic DNA from archived neonatal blood spots.

Authors:  Tara L Klassen; Janice Drabek; Torjbörn Tomson; Olafur Sveinsson; Ulrika von Döbeln; Jeffrey L Noebels; Alicia M Goldman
Journal:  J Mol Diagn       Date:  2013-03-19       Impact factor: 5.568

Review 3.  Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Authors:  Deirdre P Cronin-Fenton; Timothy L Lash
Journal:  Expert Rev Clin Pharmacol       Date:  2011-05       Impact factor: 5.045

4.  Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program.

Authors:  Daniel L Hertz; Andrew Glatz; Amy L Pasternak; Robert J Lonigro; Pankaj Vats; Yi-Mi Wu; Bailey Anderson; Erica Rabban; Erika Mora; Kevin Frank; Dan R Robinson; Rajen J Mody; Arul Chinnaiyan
Journal:  JCO Precis Oncol       Date:  2018-07-23

5.  Genome Medicine: past, present and future.

Authors:  Charles Auffray; Timothy Caulfield; Muin J Khoury; James R Lupski; Matthias Schwab; Timothy Veenstra
Journal:  Genome Med       Date:  2011-01-31       Impact factor: 11.117

6.  Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.

Authors:  Wendy Lorizio; Hope Rugo; Mary S Beattie; Simone Tchu; Teri Melese; Michelle Melisko; Alan Hb Wu; H Jeffrey Lawrence; Michele Nikoloff; Elad Ziv
Journal:  Genome Med       Date:  2011-10-04       Impact factor: 11.117

7.  Improved blood tests for cancer screening: general or specific?

Authors:  Ian A Cree
Journal:  BMC Cancer       Date:  2011-11-30       Impact factor: 4.430

8.  DTC-and-Me: Patient, Provider, Proteins and Regulators.

Authors:  Fintan R Steele; Larry Gold
Journal:  J Pers Med       Date:  2014-03-18

Review 9.  Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review.

Authors:  V L M Yip; A Alfirevic; M Pirmohamed
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 10.  Cytokines as biomarkers in rheumatoid arthritis.

Authors:  Agata Burska; Marjorie Boissinot; Frederique Ponchel
Journal:  Mediators Inflamm       Date:  2014-03-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.